Hyperkinetic disorders can be difficult to diagnose, but correct identification is critical given the development of new treatments. This session focuses on Huntington’s chorea and tardive dyskinesia, two hyperkinetic disorders for which treatments are available. The session will cover the medications used to treat these disorders, including their mechanisms, efficacy, safety, and quality of life data based on clinical trials.
Although atypical parkinsonisms share features with Parkinson’s disease, they have distinct disease courses and symptom profiles and require tailored clinical approaches. This session considers the differential diagnosis and treatment of multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and spinocerebellar ataxia.
David Shprecher, DO, MSci, FAAN is Movement Disorders Director for Banner Research and Clinical Associate Professor for University of Arizona-Phoenix. Dr. Shprecher completed a doctor of osteopathic medicine degree at Lake Erie College of Osteopathic Medicine and a Neurology residency... Read More →
Recognition of dementia in its earliest stages is now critical with the advent of new treatments, but diagnosis can be challenging given the variable patient presentations and numerous contributing causes (eg, Alzheimer’s, Lewy body dementia, vascular trauma, etc.). This session discusses the diagnosis and treatment of dementia, including the use of diagnostic biomarker tests and efficacy/safety of medications targeting amyloid-beta.
Richard S. Isaacson, MD, is a preventive neurologist and clinician researcher in the field of Alzheimer’s prevention. He founded and directed the first Alzheimer’s Prevention Clinic (APC) in the U.S. in 2013 at Weill Cornell Medicine/NewYork-Presbyterian, where he also served... Read More →
Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease dementia, and Lewy body dementia share pathological and clinical features. This session discusses the co-pathologies and the use of blood, skin, cerebrospinal fluid, and other biomarkers to aid in the differential diagnosis, and treatments to be considered including whether to split into individual pathology or clusters. Treatments to be considered include the targeting of amyloid beta for Alzheimer’s disease.
Richard S. Isaacson, MD, is a preventive neurologist and clinician researcher in the field of Alzheimer’s prevention. He founded and directed the first Alzheimer’s Prevention Clinic (APC) in the U.S. in 2013 at Weill Cornell Medicine/NewYork-Presbyterian, where he also served... Read More →
David Shprecher, DO, MSci, FAAN is Movement Disorders Director for Banner Research and Clinical Associate Professor for University of Arizona-Phoenix. Dr. Shprecher completed a doctor of osteopathic medicine degree at Lake Erie College of Osteopathic Medicine and a Neurology residency... Read More →
ATMRD Course Director, MedStar Georgetown University Hospital
Yasar Torres Yaghi, MD is a board-certified neurologist at the MedStar Georgetown University Hospital in Washington, DC and Co-Director of the Lewy Body Dementia Clinic. He obtained his medical degree from George Washington University School of Medicine, and subsequently completed... Read More →
